Pharmapedia Pro
Back to News
Approval19 Nov 2026Source: FDA

FDA Approves First Drug for Neurological Symptoms of Type 3 Gaucher Disease

The US Food and Drug Administration has approved Infilbray (venglustat) tablets as the first treatment for the neurological symptoms of Type 3 Gaucher disease in both adult and pediatric patients weighing at least 15 kg. Type 3 Gaucher disease is a rare inherited condition where fatty substances accumulate in organs, tissues, and the brain, leading to progressive neurological impairment. Infilbray acts as a glucosylceramide synthase inhibitor that crosses the blood-brain barrier to reduce the buildup of these harmful substances.

The approval is supported by data from a clinical study comparing the drug against enzyme replacement therapy. Reported side effects include gastrointestinal symptoms, adverse effects on mood, and serious psychiatric risks such as suicidal ideation and behavior. Animal studies also identified potential risks regarding vision clouding in younger patients and fetal development issues during pregnancy.

Key points

  • Infilbray (venglustat) is approved for adult and pediatric patients with Type 3 Gaucher disease weighing at least 15 kg.
  • It is the first drug approved to treat the neurological symptoms of the disease by crossing the blood-brain barrier.
  • Approval was backed by clinical study data evaluating neurological and cognitive assessments over 52 weeks.
  • Side effects include gastrointestinal issues, mood alterations, and serious psychiatric risks including suicidal ideation.

What it means for you

Clinicians and pharmacists should note this new therapeutic option for managing Type 3 Gaucher disease and its neurological manifestations. Because this is an FDA announcement, clinicians in Pakistan should check with DRAP regarding local registration and availability before advising patients.

Read the original announcement

FDA Approves First Drug to Treat Neurological Symptoms of Type 3 Gaucher Disease

Summarised automatically from the official announcement. For educational purposes only — check the original source before making clinical decisions.